193 related articles for article (PubMed ID: 28284817)
41. Effects of intravenous L-dopa on P300 and regional cerebral blood flow in parkinsonism.
Oishi M; Mochizuki Y; Hara M; Du CM; Takasu T
Int J Neurosci; 1996 Mar; 85(1-2):147-54. PubMed ID: 8727690
[TBL] [Abstract][Full Text] [Related]
42. Myocardial blood flow mapping in mice using high-resolution spin labeling magnetic resonance imaging: influence of ketamine/xylazine and isoflurane anesthesia.
Kober F; Iltis I; Cozzone PJ; Bernard M
Magn Reson Med; 2005 Mar; 53(3):601-6. PubMed ID: 15723407
[TBL] [Abstract][Full Text] [Related]
43. Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.
Quintana A; Sgambato-Faure V; Savasta M
Neurobiol Dis; 2012 Dec; 48(3):379-90. PubMed ID: 22759925
[TBL] [Abstract][Full Text] [Related]
44. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
45. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
46. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Wang Y; Wang HS; Wang T; Huang C; Liu J
J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
[TBL] [Abstract][Full Text] [Related]
47. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
48. Cardiopulmonary effects of administration of a combination solution of xylazine, guaifenesin, and ketamine or inhaled isoflurane in mechanically ventilated calves.
Kerr CL; Windeyer C; Bouré LP; Mirakhur KK; McDonell W
Am J Vet Res; 2007 Dec; 68(12):1287-93. PubMed ID: 18052732
[TBL] [Abstract][Full Text] [Related]
49. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
50. Inhaled carbon dioxide causes dose-dependent paradoxical bradypnea in animals anesthetized with pentobarbital, but not with isoflurane or ketamine.
Ginosar Y; Nachmanson NC; Shapiro J; Weissman C; Abramovitch R
Respir Physiol Neurobiol; 2015 Oct; 217():1-7. PubMed ID: 26099799
[TBL] [Abstract][Full Text] [Related]
51. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
52. Effects of Volatile Anesthetics versus Ketamine on Blood-Brain Barrier Permeability via Lipid-Mediated Alterations of Endothelial Cell Membranes.
Noorani B; Chowdhury EA; Alqahtani F; Ahn Y; Nozohouri E; Zoubi S; Patel D; Wood L; Huang J; Siddique MB; Al-Ahmad A; Mehvar R; Bickel U
J Pharmacol Exp Ther; 2023 May; 385(2):135-145. PubMed ID: 36828631
[TBL] [Abstract][Full Text] [Related]
53. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
54. L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus.
Soghomonian JJ
Eur J Neurosci; 2006 May; 23(9):2395-403. PubMed ID: 16706847
[TBL] [Abstract][Full Text] [Related]
55. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
Samadi P; Grégoire L; Morissette M; Calon F; Hadj Tahar A; Bélanger N; Dridi M; Bédard PJ; Di Paolo T
Neuropharmacology; 2008 Feb; 54(2):258-68. PubMed ID: 18001807
[TBL] [Abstract][Full Text] [Related]
56. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
57. β-Adrenergics enhance brain extraction of levodopa.
Uc EY; Dienel GA; Cruz NF; Harik SI
Mov Disord; 2002 Jan; 17(1):54-9. PubMed ID: 11835439
[TBL] [Abstract][Full Text] [Related]
58. Cerebral blood flow and BOLD fMRI responses to hypoxia in awake and anesthetized rats.
Duong TQ
Brain Res; 2007 Mar; 1135(1):186-94. PubMed ID: 17198686
[TBL] [Abstract][Full Text] [Related]
59. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
60. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
